Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
Investing.com - RBC Capital has lowered its price target on UnitedHealth Group (NYSE:UNH) to $286.00 from $355.00 while maintaining an Outperform rating on the stock. The healthcare giant, currently trading at $261 with a market capitalization of $236.53B, appears undervalued according to InvestingPro analysis.
The price target reduction comes as UnitedHealth Group recently provided new earnings guidance, which RBC Capital analyst Ben Hendrix described as setting "the EPS floor" for the company. Technical indicators from InvestingPro suggest the stock is currently in oversold territory, trading near its 52-week low of $248.88.
RBC Capital expects UnitedHealth to experience modest earnings per share growth in 2026, primarily driven by the company’s pricing actions that aim to offset continued margin headwinds.
The investment firm anticipates UnitedHealth’s growth will accelerate to the low-end of the company’s long-term annual EPS growth target of 13-16% by 2027, which RBC believes represents a more stabilized growth profile.
Despite the significant price target reduction, RBC Capital maintained its Outperform rating on UnitedHealth stock as the company works through what the firm characterized as "various industry and company specific headwinds."
In other recent news, UnitedHealth Group has been the focus of several analyst updates and projections. Cantor Fitzgerald has maintained its Overweight rating on UnitedHealth, setting a price target of $440.00, while significantly reducing its 2025 earnings per share (EPS) estimate to $16.01 from $23.01. UBS continues to hold a Buy rating with a $330.00 price target, highlighting the company’s strategic navigation of Medicare Advantage challenges and projecting a 10% cost trend for 2026. Meanwhile, Oppenheimer has lowered its price target to $325, maintaining an Outperform rating and noting that UnitedHealth’s 2025 EPS guidance could represent a low point before growth resumes in 2026. Piper Sandler also reduced its price target to $317.00, maintaining an Overweight rating and commending the transparency shown in UnitedHealth’s earnings call regarding its business mix and pricing assumptions. Mizuho (NYSE:MFG) has kept its Outperform rating with a $350.00 price target, pointing out ongoing pricing pressures and elevated medical costs expected through 2026. These developments reflect a period of adjustment and strategic positioning for UnitedHealth as it addresses various financial and operational challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.